Facing Aricept Expiration, Eisai Maximizes Product Value
This article was originally published in PharmAsia News
Executive Summary
Eisai is speeding up the launch of a new high-dose Aricept (donepezil) to maximize product value as the Alzheimer's disease drug will lose patent protection at the end of this month